NYSE:PLX
Protalix BioTherapeutics Inc Stock News
$1.25
+0.0300 (+2.46%)
At Close: Mar 27, 2024
Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022
06:50am, Monday, 07'th Nov 2022
Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Nov. 7, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company
Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06:50am, Tuesday, 06'th Sep 2022
CARMIEL, Israel , Sept. 6, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercializati
Protalix BioTherapeutics Inc. (PLX) CEO Dror Bashan on Q2 2022 Results - Earnings Call Transcript
11:51am, Monday, 15'th Aug 2022
Protalix BioTherapeutics Inc. (NYSE:PLX ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Chuck Padala - LifeSci Advisors, Investor Relations Dror Bashan - President,
Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022
06:50am, Monday, 08'th Aug 2022
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , Aug. 8, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical compan
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q1 2022 Results - Earnings Call Transcript
09:48am, Monday, 16'th May 2022
Protalix BioTherapeutics Inc. (NYSE:PLX ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Alexandra Schuman - LifeSci Advisors, IR Dror Bashan - President & CEO Eyal Rubi
Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial
12:22pm, Monday, 04'th Apr 2022
Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., have announced topline data from the BALANCE Phase 3 trial evaluating pegunigalsida
Protalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2021 Results - Earnings Call Transcript
10:41am, Thursday, 31'st Mar 2022
Protalix BioTherapeutics (PLX) CEO, Dror Bashan on Q4 2021 Results - Earnings Call Transcript
Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022
06:50am, Thursday, 24'th Mar 2022
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 24, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical co
Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease
10:09am, Friday, 18'th Mar 2022
Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A, have announced final results from the BRIGHT Phase 3 trial of pegunigalsidase alfa (P
Botanical and Plant-Derived Drugs Market to Grow by USD 15.89 bn | Technavio
04:00am, Tuesday, 01'st Mar 2022 Kwhen FinanceProtalix, Chiesi Global file for EU approval of PRX-102 for Fabry disease
01:01pm, Thursday, 24'th Feb 2022 Seeking Alpha
Protalix BioTherapeutics (PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., submitted an application via centralized procedure to the European Medicines…
Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium 2022
11:50am, Thursday, 03'rd Feb 2022 Kwhen FinanceProtalix Biotherapeutics: Is It Worth The Wait?
01:30pm, Friday, 07'th Jan 2022 Seeking AlphaProtalix Biotherapeutics: Is It Worth The Wait?
08:30am, Friday, 07'th Jan 2022
Protalix concluded its Type A meeting with the US Food and Drug Administration (FDA), providing a way forward with its lead indication PRX-102. Protalix published top line results of the interim analy
Have an attention on: PolarityTE, Inc. (NASDAQ:PTE), Protalix BioTherapeutics, Inc. (AMEX:PLX)
04:40am, Friday, 24'th Dec 2021 Stock Equity
PolarityTE, Inc. (NASDAQ:PTE) with the stream of 1.65% also noticed, India Protalix BioTherapeutics, Inc. (AMEX:PLX) encountered a rapid change of 5.26% in the last hour of Thursdays trading session. PolarityTE, The post Have an attention on: PolarityTE, Inc. (NASDAQ:PTE), Protalix BioTherapeutics, Inc. (AMEX:PLX) appeared first on Stocks Equity .